Glaukos price target raised to $149 from $140 at BTIG

BTIG analyst Ryan Zimmerman raised the firm’s price target on Glaukos (GKOS) to $149 from $140 and keeps a Buy rating on the shares. The MedTech tape has been up 3.2% since earnings season kicked off on October 15, the analyst tells investors in a research note. Following the U.S. election, BTIG believes devices, an area that generally gets bipartisan support, should be in a stronger relative position within the healthcare landscape under various scenarios.